EUVIMEDEUVIMED entdecken
Crossref

hURAT1 Transgenic Mouse Model for Evaluating Targeted Urate‐Lowering Agents

Weiyan Cai iD, Miyi Yang iD, Qinghe Zhao, Guohua Yi, Peihui Lin, Apeng Chen iD, Gejing De iD

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Weiyan Cai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Hyperuricemia, Disease Models, Animal, Organic Anion Transporters, Uric Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: the Fundamental Research Funds for the Central Public Welfare Research Institutes, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urate transporter 1 (URAT1) is a well‐known therapeutic target for reducing urate levels in the treatment of hyperuricemia and gout. However, current pharmacological studies have failed to evaluate the efficacy of URAT1 inhibitors in non‐primate animal models. We established a human URAT1 ( hURAT1 ) transgenic knock‐in (KI) mouse model to assess uricosuric agents' effectiveness and characterize URAT1‐caused pathogenesis.

Methods

We generated hURAT1 transgenic mice using CRISPR/Cas9 KI technique. mUrat1 knockout was achieved by replacing exon 1 coding sequence with a human SLC22A12 coding sequence (CDS)‐pA cassette. Based on the above transgenic mice, a hyperuricemia model was further established by hypoxanthine administration.

Results

The hURAT1 ‐KI mice successfully expressed hURAT1 protein to the apical side of the kidney proximal tubule epithelium, where native human URAT1 is localized in human kidney. Upon hypoxanthine challenge, the blood uric acid (UA) level was elevated in hURAT1‐ KI mice (251 μmol/L), showing an approximately 37% increase compared to wild‐type (WT) mice (183.5 μmol/L). The elevated blood UA level could be alleviated by hURAT1 inhibitor benzbromarone treatment in the hURAT1 ‐KI mice (164.2 μmol/L vs. 251 μmol/L, p < 0.05) whereas no response was observed in WT littermates (168.8 μmol/L vs. 183.5 μmol/L).

Conclusion

The hURAT1 ‐KI hyperuricemia mouse model would be valuable for preclinical evaluation of gout treatment with urate‐lowering drugs and for studying UA metabolic complexities in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaDisease Models, AnimalOrganic Anion TransportersUric AcidOrganic Cation Transport ProteinsMice, TransgenicAnimalsHumansUricosuric AgentsGoutMice, Inbred C57BLMaleGout SuppressantsPhenotypeGene Knock-In TechniquesHypoxanthineMiceCRISPR-Cas Systems

Stichwörter der Autor:innen

SLC22A12URAT1gouthyperuricemiatransporteruric acid

Substanzen

Organic Anion TransportersUric AcidOrganic Cation Transport ProteinsSLC22A12 protein, humanUricosuric AgentsGout SuppressantsHypoxanthine

Autor:innen und Institutionen

  • Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
  • Department of Medicine, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
  • Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
  • Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
  • Division of Nephrology, Department of Internal Medicine, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Department of Respiratory, Children's Hospital of Nanjing MedicalUniversity, Nanjing, Jiangsu, China.

ORCID-Profile: Weiyan Cai, Miyi Yang, Apeng Chen, Gejing De

Förderung

  • the Fundamental Research Funds for the Central Public Welfare Research Institutes
  • National Natural Science Foundation of China

Zitieren

APA

Cai, W., Yang, M., Zhao, Q., Yi, G., Lin, P., Chen, A., & De, G. (2025). hURAT1 Transgenic Mouse Model for Evaluating Targeted Urate‐Lowering Agents. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70034

Vancouver

Cai W, Yang M, Zhao Q, Yi G, Lin P, Chen A, et al. hURAT1 Transgenic Mouse Model for Evaluating Targeted Urate‐Lowering Agents. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70034

BibTeX
@article{Cai2025,
  author = {Cai, Weiyan and Yang, Miyi and Zhao, Qinghe and Yi, Guohua and Lin, Peihui and Chen, Apeng and De, Gejing},
  title = {hURAT1 Transgenic Mouse Model for Evaluating Targeted Urate‐Lowering Agents},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70034}
}
Kostenlos starten →